Cargando…

Ovarian Metastases from ALK-rearranged Lung Adenocarcinoma: A Case Report and Literature Review

We herein report a 37-year-old woman with lung adenocarcinoma with brain metastases and an asymptomatic ovarian tumor. Immunohistochemistry and a fluorescent in situ hybridization analysis of the biopsied lung tumor revealed anaplastic lymphoma kinase (ALK) gene rearrangement. Although the origin of...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasano, Hajime, Sekine, Akimasa, Hirata, Toru, Iwamoto, Keisuke, Itou, Yuhei, Itani, Hidetoshi, Kondou, Shigeto, Tokui, Toshiya, Tanigawa, Motoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287983/
https://www.ncbi.nlm.nih.gov/pubmed/29984766
http://dx.doi.org/10.2169/internalmedicine.0538-17
Descripción
Sumario:We herein report a 37-year-old woman with lung adenocarcinoma with brain metastases and an asymptomatic ovarian tumor. Immunohistochemistry and a fluorescent in situ hybridization analysis of the biopsied lung tumor revealed anaplastic lymphoma kinase (ALK) gene rearrangement. Although the origin of the ovarian tumor remained unclear, alectinib administration was initiated, and radiological responses were observed in all lesions, which confirmed that the ovarian tumor was a metastasis from lung cancer. Although differentiating the origin of an ovarian tumor is difficult in lung cancer patients due to the rarity of ovarian metastases, alectinib therapy can replace an invasive biopsy, especially in ALK-rearranged lung cancer patients.